

# Robert W Frenck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3514101/publications.pdf>

Version: 2024-02-01

50  
papers

19,534  
citations

257450

24  
h-index

243625

44  
g-index

53  
all docs

53  
docs citations

53  
times ranked

27192  
citing authors

#	ARTICLE	IF	CITATIONS
1	A site assessment tool for inpatient controlled human infection models for enteric disease pathogens. <i>Clinical Trials</i> , 2022, 19, 116-118.	1.6	0
2	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.	27.0	431
3	Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. <i>Clinical Infectious Diseases</i> , 2022, 75, 390-398.	5.8	60
4	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. <i>Clinical Infectious Diseases</i> , 2021, 73, 336-340.	5.8	70
5	Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e234-e235.	2.0	2
6	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	27.0	709
7	<i>Shigella</i>-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either <i>Shigella flexneri</i> 2a or <i>Shigella sonnei</i> . <i>MSphere</i> , 2021, 6, e0012221.	2.9	12
8	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.	27.0	346
9	Efficacy, safety, and immunogenicity of the <i>Shigella sonnei</i> 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. <i>EClinicalMedicine</i> , 2021, 39, 101076.	7.1	37
10	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	27.0	1,090
11	Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live <i>Shigella sonnei</i> vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding. <i>PLoS ONE</i> , 2021, 16, e0259361.	2.5	4
12	<i>Shigella</i> -Controlled Human Infection Models: Current and Future Perspectives. <i>Current Topics in Microbiology and Immunology</i> , 2021, , .	1.1	1
13	Immune Response Characterization after Controlled Infection with Lyophilized <i>Shigella sonnei</i> 53G. <i>MSphere</i> , 2020, 5, .	2.9	25
14	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	27.0	2,107
15	Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	27.8	1,197
16	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	27.0	11,472
17	Establishment of a Controlled Human Infection Model with a Lyophilized Strain of <i>Shigella sonnei</i> 53G. <i>MSphere</i> , 2020, 5, .	2.9	13
18	Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel <i>Staphylococcus aureus</i> 4-Antigen Vaccine (SA4Ag). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz532.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of a vaccine for extra-intestinal pathogenic <i>Escherichia coli</i> (ESTELLA): a phase 2 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 631-640.	9.1	53
20	Consensus Report on <i>Shigella</i> Controlled Human Infection Model: Conduct of Studies. <i>Clinical Infectious Diseases</i> , 2019, 69, S580-S590.	5.8	24
21	Consensus Report on <i>Shigella</i> Controlled Human Infection Model: Clinical Endpoints. <i>Clinical Infectious Diseases</i> , 2019, 69, S591-S595.	5.8	23
22	A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against <i>Shigella sonnei</i> . <i>Vaccine</i> , 2018, 36, 4880-4889.	3.8	30
23	Developing and utilizing controlled human models of infection. <i>Vaccine</i> , 2017, 35, 6813-6818.	3.8	20
24	Lot-to-lot consistency, safety and immunogenicity of 3 lots of <i>Haemophilus influenzae</i> type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. <i>Vaccine</i> , 2017, 35, 3564-3574.	3.8	2
25	Safety, tolerability, and immunogenicity of a 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. <i>Vaccine</i> , 2017, 35, 375-384.	3.8	52
26	Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen <i>Staphylococcus aureus</i> vaccine in healthy older adults: Results of a randomised trial. <i>Vaccine</i> , 2017, 35, 385-394.	3.8	43
27	The Dynamics of <i>Staphylococcus aureus</i> carriage and Comparisons by Age in Two Studies of an Investigational <i>S aureus</i> 4-Antigen Vaccine (SA4Ag). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
28	Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. <i>Vaccine</i> , 2016, 34, 3454-3462.	3.8	22
29	Pharmacokinetics and pharmacogenomics of $\beta$ -lactam-induced neutropenia. <i>Pharmacogenomics</i> , 2016, 17, 547-559.	1.3	7
30	Response to Letter to the Editor regarding: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18 to 49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. <i>Vaccine</i> , 2016, 34, 4467.	3.8	0
31	Melody Valve <i>Bartonella henselae</i> Endocarditis in an Afebrile Teen: A Case Report. <i>Pediatrics</i> , 2016, 137, .	2.1	9
32	A cross-sectional household cluster serosurvey of hepatitis C virus antibodies in an urban slum of Cairo, Egypt in 2004. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2015, 1, 9.	2.2	1
33	Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2015, 211, 870-878.	4.0	223
34	Serological Correlates of Protection against a GII.4 Norovirus. <i>Vaccine Journal</i> , 2015, 22, 923-929.	3.1	109
35	599Rapid rises in antibody titers observed following single dose administration of a novel 4-antigen <i>Staphylococcus aureus</i> vaccine (SA4Ag) to healthy adults. <i>Open Forum Infectious Diseases</i> , 2014, 1, S25-S25.	0.9	0
36	1098The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions. <i>Open Forum Infectious Diseases</i> , 2014, 1, S324-S324.	0.9	0

#	ARTICLE	IF	CITATIONS
37	1102 Immunogenicity and Safety of a Second Administration of 13-Valent Pneumococcal Conjugate Vaccine Five Years after Initial Vaccination in Adults 50 Years and Older. <i>Open Forum Infectious Diseases</i> , 2014, 1, S325-S326.	0.9	0
38	13-valent Pneumococcal Conjugate Vaccine in Older Children and Adolescents Either Previously Immunized With or Naïve to 7-valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 183-189.	2.0	25
39	Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. <i>Vaccine</i> , 2014, 32, 2364-2374.	3.8	136
40	Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. <i>Vaccine</i> , 2013, 31, 3594-3602.	3.8	132
41	Immunogenicity, Safety and Tolerability of 3 Lots of 13-valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations in the United States. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 871-880.	2.0	19
42	Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults. <i>Vaccine Journal</i> , 2012, 19, 1296-1303.	3.1	64
43	Predicting Susceptibility to Norovirus GII.4 by Use of a Challenge Model Involving Humans. <i>Journal of Infectious Diseases</i> , 2012, 206, 1386-1393.	4.0	124
44	The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 63-77.	3.1	20
45	Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. <i>Vaccine</i> , 2011, 29, 5666-5674.	3.8	63
46	Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 1086-1091.	2.0	32
47	Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. <i>Arthritis Care and Research</i> , 2010, 62, 903-906.	3.4	4
48	Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2010, 105, 148-154.	0.4	171
49	Patients with Inflammatory Bowel Disease Are at Risk for Vaccine-Preventable Illnesses. <i>American Journal of Gastroenterology</i> , 2006, 101, 1834-1840.	0.4	304
50	Development of Pathogenicity-Driven Definitions of Outcomes for a Field Trial of a Killed Oral Vaccine against Enterotoxigenic <i>Escherichia coli</i> in Egypt: Application of an Evidence-Based Method. <i>Journal of Infectious Diseases</i> , 2004, 189, 2299-2307.	4.0	32